公开(公告)号：US08741622B2

公开(公告)日：2014-06-03

申请号：US13847787

申请日：2013-03-20

Applicant: Nestec S.A.

Inventor： Bernard Berger ,  Enea Rezzonico ,  Fabrizio Arigoni

IPC: C12N1/00

CPC classification number: C12N15/87 ,  A23C9/1234 ,  A23L33/135 ,  C12N1/20 ,  C12N15/01 ,  C12N15/64 ,  C12R1/01

Abstract: The present invention relates in general to the field of Bifidobacteria. In particular, the present invention relates to the field of Bifidobacteria with a modulated stress resistance. One embodiment of the present invention is a Bifidobacterium with a constitutively modulated DnaK, GrpE and/or CIpB expression.

Abstract translation: 本发明一般涉及双歧杆菌的领域。 特别地，本发明涉及具有调制的抗应力的双歧杆菌的领域。 本发明的一个实施方案是具有组成型调节的DnaK，GrpE和/或CIpB表达的双歧杆菌。

公开(公告)号：US20180220691A1

公开(公告)日：2018-08-09

申请号：US15749536

申请日：2016-08-04

Applicant: NESTEC S.A.

Inventor： Clara Lucia Garcia-Rodenas ,  Bernard Berger ,  Enea Rezzonico

IPC: A23L33/135 ,  A23L33/00 ,  A61K35/745

Abstract: The invention relates to a nutrition composition with promoting or inducing a gut microbiota that is closer to infants fed exclusively with human breast milk, in comparison to infant fed with conventional nutritional composition. The composition is in particular intended for infants between 0 and 12 months of age fed predominantly with infant formula. The infants can be fed during 2, 4, or 6 months and the composition can be an infant formula. The composition promotes a healthy intestinal flora and has beneficial long and short terms effects.

公开(公告)号：US20130273660A1

公开(公告)日：2013-10-17

申请号：US13847787

申请日：2013-03-20

Applicant: Nestec S.A.

Inventor： Bernard Berger ,  Enea Rezzonico ,  Fabrizio Arigoni

IPC: C12N1/20

CPC classification number: C12N15/87 ,  A23C9/1234 ,  A23L33/135 ,  C12N1/20 ,  C12N15/01 ,  C12N15/64 ,  C12R1/01

Abstract: The present invention relates in general to the field of Bifidobacteria. In particular, the present invention relates to the field of Bifidobacteria with a modulated stress resistance. One embodiment of the present invention is a Bifidobacterium with a constitutively modulated DnaK, GrpE and/or CIpB expression.

Abstract translation: 本发明一般涉及双歧杆菌的领域。 特别地，本发明涉及具有调制的抗应力的双歧杆菌的领域。 本发明的一个实施方案是具有组成型调节的DnaK，GrpE和/或CIpB表达的双歧杆菌。

公开(公告)号：US09962415B2

公开(公告)日：2018-05-08

申请号：US14787817

申请日：2014-05-01

Applicant: NESTEC S.A.

Inventor： Christian Darimont-Nicolau ,  Bernard Berger ,  Enea Rezzonico ,  Catherine Ngom-Bru ,  Melissa LePage

IPC: A01N63/00 ,  A61K35/747 ,  A61K8/99 ,  C12Q1/04 ,  A61Q19/06 ,  C12Q1/06 ,  A23L33/135

CPC classification number: A61K35/747 ,  A23L33/135 ,  A23V2002/00 ,  A23Y2220/73 ,  A61K8/99 ,  A61K2800/92 ,  A61Q19/06 ,  C12Q1/04 ,  C12Q1/06 ,  G01N2333/33 ,  G01N2800/044 ,  A23V2200/3204 ,  A23V2200/332

Abstract: The present invention relates to means and methods for modulating the gut microbiota composition of a subject, preferably a human. In particular, the present invention provides an agent capable of reducing the proportion of Lachnospiraceae in the gut microbiota composition of a subject which agent is useful for promoting weight loss or preventing weight gain in a subject, preferably an obese or overweight subject. Lactobacillus rhamnosus CGMCC 1.3724 is particularly preferred as the agent provided by and used in the present invention.

公开(公告)号：US20160089404A1

公开(公告)日：2016-03-31

申请号：US14787817

申请日：2014-05-01

Applicant: NESTEC S.A.

Inventor： Christian Darimont-Nicolau ,  Bernard Berger ,  Enea Rezzonico ,  Catherine Ngom-Bru ,  Melissa LePage

IPC: A61K35/747 ,  C12Q1/06

CPC classification number: A61K35/747 ,  A23L33/135 ,  A23V2002/00 ,  A23Y2220/73 ,  A61K8/99 ,  A61K2800/92 ,  A61Q19/06 ,  C12Q1/04 ,  C12Q1/06 ,  G01N2333/33 ,  G01N2800/044 ,  A23V2200/3204 ,  A23V2200/332

Abstract: The present invention relates to means and methods for modulating the gut microbiota composition of a subject, preferably a human. In particular, the present invention provides an agent capable of reducing the proportion of Lachnospiraceae in the gut microbiota composition of a subject which agent is useful for promoting weight loss or preventing weight gain in a subject, preferably an obese or overweight subject. Lactobacillus rhamnosus CGMCC 1.3724 is particularly preferred as the agent provided by and used in the present invention.

Abstract translation: 本发明涉及用于调节受试者，优选人的肠道微生物群组成的方法和方法。 特别地，本发明提供一种能够减少受试者的肠道微生物群组合物中Lachnospiraceae的比例的试剂，该试剂可用于促进体重减轻或预防受试者，优选肥胖或超重受试者的体重增加。 作为由本发明提供并用于本发明的试剂，特别优选鼠李糖乳杆菌CGMCC1.3724。